$54.99
0.771.43%
Dernière mise à jour: 1:57 PM
Comments
Loading...
Évaluations des analystes, objectifs de prix, prévision
BioMarin Pharmaceutical Inc a un objectif de cours consensuel de $92.79 basé sur les évaluations de 30 analystes. Le plus élevé est $140, publié par Truist Securities le septembre 25, 2023. Le plus bas est $55, publié par HC Wainwright & Co. le octobre 27, 2025. Les 3 évaluations d’analystes les plus récentes ont été publiées par Stifel, Bernstein et Truist Securities le novembre 6, 2025, novembre 3, 2025 et octobre 28, 2025, respectivement. Avec un objectif de cours moyen de $76.33 entre Stifel, Bernstein et Truist Securities, il existe une variation implicite de 38.80% upside pour BioMarin Pharmaceutical Inc selon ces dernières évaluations d’analystes.
Sociétés d'analyse émettant des recommandations1
Stifel
Bernstein
Truist Securities
Wells Fargo
Barclays
1calculé à partir des notes des analystes
Notes d'analystes pour BioMarin Pharmaceutical
Buy Now | Get Alert | |||||||
|---|---|---|---|---|---|---|---|---|
11/06/2025 | 10.92% | Stifel | $73 → $61 | Downgrade | Buy → Hold | |||
11/03/2025 | 60.01% | Bernstein | $95 → $88 | Maintains | Outperform | |||
10/28/2025 | 45.47% | Truist Securities | $90 → $80 | Maintains | Buy | |||
10/28/2025 | 27.28% | Wells Fargo | $90 → $70 | Maintains | Overweight | |||
10/28/2025 | 32.74% | Stifel | $91 → $73 | Maintains | Buy | |||
10/28/2025 | 45.47% | Barclays | $86 → $80 | Maintains | Overweight | |||
10/28/2025 | 78.2% | Morgan Stanley | $104 → $98 | Maintains | Overweight | |||
10/27/2025 | 0.01% | HC Wainwright & Co. | $60 → $55 | Maintains | Neutral | |||
10/09/2025 | 116.38% | JP Morgan | $116 → $119 | Maintains | Overweight | |||
09/08/2025 | 9.1% | HC Wainwright & Co. | → $60 | Initiates | → Neutral | |||
08/06/2025 | 92.74% | Guggenheim | $101 → $106 | Maintains | Buy | |||
08/05/2025 | 107.29% | UBS | $113 → $114 | Maintains | Buy | |||
07/22/2025 | 74.56% | Morgan Stanley | $97 → $96 | Maintains | Overweight | |||
07/14/2025 | 105.47% | JP Morgan | $108 → $113 | Maintains | Overweight | |||
05/05/2025 | 89.11% | Goldman Sachs | $124 → $104 | Maintains | Buy | |||
05/02/2025 | 41.83% | Citigroup | $82 → $78 | Maintains | Neutral | |||
02/24/2025 | 78.2% | Oppenheimer | → $98 | Upgrade | Perform → Outperform | |||
02/20/2025 | 45.47% | Scotiabank | $78 → $80 | Maintains | Sector Perform | |||
02/20/2025 | 49.1% | Citigroup | $81 → $82 | Maintains | Neutral | |||
02/20/2025 | 27.28% | RBC Capital | $70 → $70 | Reiterates | Sector Perform → Sector Perform | |||
02/20/2025 | 63.65% | Cantor Fitzgerald | $90 → $90 | Reiterates | Overweight → Overweight | |||
02/20/2025 | 105.47% | UBS | $109 → $113 | Maintains | Buy | |||
02/20/2025 | 129.11% | Piper Sandler | $122 → $126 | Maintains | Overweight | |||
02/20/2025 | 87.29% | B of A Securities | $99 → $103 | Maintains | Buy | |||
12/12/2024 | 63.65% | Cantor Fitzgerald | $90 → $90 | Reiterates | Overweight → Overweight | |||
11/15/2024 | 72.74% | Wolfe Research | → $95 | Initiates | → Outperform | |||
10/30/2024 | 47.29% | Citigroup | $93 → $81 | Maintains | Neutral | |||
10/30/2024 | 52.74% | Canaccord Genuity | $93 → $84 | Maintains | Hold | |||
10/30/2024 | 63.65% | Cantor Fitzgerald | $110 → $90 | Maintains | Overweight | |||
10/30/2024 | 98.2% | JP Morgan | $110 → $109 | Maintains | Overweight | |||
10/30/2024 | 45.47% | RBC Capital | $80 → $80 | Reiterates | Sector Perform → Sector Perform | |||
10/30/2024 | 90.93% | Evercore ISI Group | $115 → $105 | Maintains | Outperform | |||
10/30/2024 | 92.74% | UBS | $104 → $106 | Maintains | Buy | |||
10/30/2024 | 18.19% | Baird | $72 → $65 | Maintains | Neutral | |||
10/30/2024 | — | William Blair | — | Downgrade | Outperform → Market Perform | |||
10/10/2024 | 43.65% | Raymond James | → $79 | Reinstates | → Outperform | |||
10/04/2024 | 45.47% | RBC Capital | $85 → $80 | Maintains | Sector Perform | |||
10/04/2024 | 56.38% | Barclays | $110 → $86 | Maintains | Overweight | |||
09/17/2024 | 41.83% | Scotiabank | $95 → $78 | Maintains | Sector Perform | |||
09/17/2024 | 63.65% | Truist Securities | $118 → $90 | Maintains | Buy | |||
09/17/2024 | 63.65% | Wells Fargo | $115 → $90 | Maintains | Overweight | |||
09/17/2024 | 54.56% | RBC Capital | $100 → $85 | Maintains | Sector Perform | |||
09/17/2024 | 109.11% | B of A Securities | $130 → $115 | Maintains | Buy | |||
09/17/2024 | 58.2% | Stifel | $115 → $87 | Maintains | Buy | |||
09/17/2024 | 63.65% | Bernstein | $116 → $90 | Maintains | Outperform | |||
09/13/2024 | 69.11% | Canaccord Genuity | $93 → $93 | Maintains | Hold | |||
09/09/2024 | 100.02% | Cantor Fitzgerald | $110 → $110 | Reiterates | Overweight → Overweight | |||
09/05/2024 | 118.2% | JP Morgan | $111 → $120 | Maintains | Overweight | |||
09/05/2024 | 81.83% | RBC Capital | $100 → $100 | Reiterates | Sector Perform → Sector Perform | |||
09/05/2024 | 72.74% | Scotiabank | $86 → $95 | Maintains | Sector Perform | |||
09/05/2024 | 114.56% | Truist Securities | $140 → $118 | Maintains | Buy | |||
09/05/2024 | 121.84% | Piper Sandler | $107 → $122 | Maintains | Overweight | |||
08/27/2024 | 94.56% | Piper Sandler | $107 → $107 | Maintains | Overweight | |||
08/21/2024 | 109.11% | Stifel | $112 → $115 | Maintains | Buy | |||
08/20/2024 | 100.02% | Bernstein | $94 → $110 | Upgrade | Market Perform → Outperform | |||
08/06/2024 | 118.2% | TD Cowen | $125 → $120 | Maintains | Buy | |||
08/06/2024 | 56.38% | Scotiabank | $85 → $86 | Maintains | Sector Perform | |||
08/06/2024 | 103.65% | Stifel | $108 → $112 | Maintains | Buy | |||
08/06/2024 | 81.83% | RBC Capital | $100 → $100 | Reiterates | Sector Perform → Sector Perform | |||
08/06/2024 | 100.02% | Barclays | $111 → $110 | Maintains | Overweight | |||
08/06/2024 | 109.11% | Evercore ISI Group | $113 → $115 | Maintains | Outperform | |||
08/05/2024 | 100.02% | Cantor Fitzgerald | $110 → $110 | Reiterates | Overweight → Overweight | |||
07/25/2024 | 61.83% | Canaccord Genuity | $89 → $89 | Maintains | Hold | |||
07/22/2024 | 100.02% | Cantor Fitzgerald | $110 → $110 | Reiterates | Overweight → Overweight | |||
06/27/2024 | 109.11% | Wells Fargo | $110 → $115 | Maintains | Overweight | |||
05/17/2024 | 30.92% | Baird | $104 → $72 | Downgrade | Outperform → Neutral | |||
05/14/2024 | 105.47% | Evercore ISI Group | → $113 | Initiates | → Outperform | |||
04/26/2024 | 103.65% | Morgan Stanley | $115 → $112 | Maintains | Overweight | |||
04/26/2024 | 61.83% | Canaccord Genuity | $91 → $89 | Maintains | Hold | |||
04/25/2024 | 100.02% | Cantor Fitzgerald | $110 → $110 | Reiterates | Overweight → Overweight | |||
04/25/2024 | 65.47% | Citigroup | $94 → $91 | Maintains | Neutral | |||
04/25/2024 | 54.56% | Scotiabank | $83 → $85 | Maintains | Sector Perform | |||
04/25/2024 | 100.02% | Wells Fargo | $100 → $110 | Maintains | Overweight | |||
02/29/2024 | 65.47% | Canaccord Genuity | → $91 | Reiterates | Hold → Hold | |||
02/23/2024 | 81.83% | Cantor Fitzgerald | $100 → $100 | Reiterates | Overweight → Overweight | |||
02/23/2024 | 81.83% | RBC Capital | $100 → $100 | Reiterates | Sector Perform → Sector Perform | |||
02/23/2024 | 94.56% | Piper Sandler | $115 → $107 | Maintains | Overweight | |||
01/30/2024 | 89.11% | Baird | $127 → $104 | Maintains | Outperform | |||
12/21/2023 | 83.65% | Stifel | $101 → $101 | Reiterates | Buy → Buy | |||
11/07/2023 | 81.83% | RBC Capital | $100 → $100 | Reiterates | Sector Perform → Sector Perform | |||
11/03/2023 | 81.83% | BMO Capital | $102 → $100 | Maintains | Outperform | |||
11/02/2023 | 109.11% | Piper Sandler | $125 → $115 | Maintains | Overweight | |||
11/02/2023 | 112.75% | Morgan Stanley | $125 → $117 | Maintains | Overweight | |||
11/02/2023 | 101.84% | Barclays | $125 → $111 | Maintains | Overweight | |||
11/02/2023 | 81.83% | Cantor Fitzgerald | $120 → $100 | Maintains | Overweight | |||
11/01/2023 | 83.65% | Stifel | $108 → $101 | Maintains | Buy | |||
10/23/2023 | 49.1% | Bernstein | → $82 | Upgrade | Underperform → Market Perform | |||
10/16/2023 | 118.2% | Cantor Fitzgerald | → $120 | Reiterates | Overweight → Overweight | |||
09/28/2023 | — | Raymond James | — | Initiates | → Market Perform | |||
09/25/2023 | 154.57% | Truist Securities | → $140 | Reiterates | Buy → Buy | |||
09/18/2023 | 118.2% | UBS | → $120 | Initiates | → Buy | |||
09/15/2023 | 154.57% | Truist Securities | → $140 | Reiterates | Buy → Buy | |||
09/14/2023 | 118.2% | Cantor Fitzgerald | → $120 | Reiterates | Overweight → Overweight | |||
09/13/2023 | 100.02% | Guggenheim | → $110 | Reiterates | Buy → Buy | |||
09/13/2023 | 81.83% | RBC Capital | → $100 | Reiterates | Sector Perform → Sector Perform | |||
09/13/2023 | 118.2% | Cantor Fitzgerald | → $120 | Reiterates | Overweight → Overweight | |||
08/01/2023 | 127.29% | Morgan Stanley | $129 → $125 | Maintains | Overweight | |||
08/01/2023 | 96.38% | Stifel | $118 → $108 | Maintains | Buy | |||
08/01/2023 | 27.28% | Wedbush | $73 → $70 | Maintains | Neutral | |||
08/01/2023 | 118.2% | Cantor Fitzgerald | → $120 | Reiterates | Overweight → Overweight |
FAQ
Quel est le cours indicatif de l'action BioMarin Pharmaceutical (BMRN) ?
Le dernier objectif de prix pour BioMarin Pharmaceutical (NASDAQ:BMRN) a été rapporté par Stifel le novembre 6, 2025. Le cabinet d'analystes a fixé un objectif de prix pour $61.00 s'attendant à ce que BMRN se rise dans les 12 prochains mois (un possible changement de 10.92% upside). 26 cabinets d'analystes ont rapporté des notes au cours de la dernière année.
Quelle est la note d'analyste la plus récente pour BioMarin Pharmaceutical (BMRN) ?
La dernière note d'analyste pour BioMarin Pharmaceutical (NASDAQ:BMRN) a été fournie par Stifel, et BioMarin Pharmaceutical réduit leur note hold.
Quand a eu lieu la dernière mise à niveau pour BioMarin Pharmaceutical (BMRN) ?
La dernière amélioration pour BioMarin Pharmaceutical Inc a eu lieu le février 24, 2025 lorsque Oppenheimer a augmenté leur objectif de prix à $98. Oppenheimer avait précédemment a perform pour BioMarin Pharmaceutical Inc.
Quand a eu lieu la dernière dégradation pour BioMarin Pharmaceutical (BMRN) ?
La dernière réduction pour BioMarin Pharmaceutical Inc a eu lieu le novembre 6, 2025 lorsque Stifel a changé leur objectif de prix de $73 à $61 pour BioMarin Pharmaceutical Inc.
Quand la prochaine note d'analyste sera-t-elle publiée ou mise à jour pour BioMarin Pharmaceutical (BMRN) ?
Les analystes arrivent à des évaluations d'actions après avoir effectué des recherches approfondies, ce qui inclut l'examen des états financiers publics, la discussion avec les dirigeants et les clients de BioMarin Pharmaceutical, et l'écoute des conférences téléphoniques sur les résultats. La plupart des analystes font cela tous les trois mois, vous devriez donc obtenir 4 notes par entreprise par société chaque année. La dernière note pour BioMarin Pharmaceutical a été déposée le novembre 6, 2025, donc vous devriez vous attendre à ce que la prochaine note soit disponible vers novembre 6, 2026.
La note d'analyste pour BioMarin Pharmaceutical (BMRN) est-elle correcte ?
Bien que les évaluations soient subjectives et changeront, la dernière note de BioMarin Pharmaceutical (BMRN) était un réduit avec un objectif de prix de $73.00 à $61.00. Le prix actuel de BioMarin Pharmaceutical (BMRN) est de $55.00, ce qui est out of la fourchette prédite par l'analyste.
Parcourir notes d'analystes et objectifs de cours sur toutes les actions.